ArticleJournal of fungi (Basel, Switzerland)2022
In Vitro Antifungal Activity of LL-37 Analogue Peptides against
Article in Journal of fungi (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Optimized LL-37-Derived Peptides Exhibit Antitubercular Activity, Induce Membrane Disruption, and P-Type ATPase Transcriptional Responses inBiomolecules · 2026Article
- Antimicrobial Peptides of the Cathelicidin Family: Focus on LL-37 and Its Modifications.International journal of molecular sciences · 2025Review
- Antimicrobial Peptides Act-6 and Act 8-20 Derived from Scarabaeidae Cecropins Exhibit Differential Antifungal Activity.Journal of fungi (Basel, Switzerland) · 2025Article
- Review
- The Contribution of Human Antimicrobial Peptides to Fungi.International journal of molecular sciences · 2025Review
- Hospital Acquired Sepsis, Disease Prevalence, and Recent Advances in Sepsis Mitigation.Pathogens (Basel, Switzerland) · 2024Review
- Exploring the frontiers of therapeutic breadth of antifungal peptides: A new avenue in antifungal drugs.Journal of industrial microbiology & biotechnology · 2024Review
- Pore-forming peptide C14R exhibits potent antifungal activity against clinical isolates ofFrontiers in cellular and infection microbiology · 2024Article
- Article
- Epithelial-Immune Cell Crosstalk Determines the Activation of Immune Cells In Vitro by the Human Cathelicidin LL-37 at Low Physiological Concentrations.Biomolecules · 2023Article
- Antimicrobial Peptides Demonstrate Activity against Resistant Bacterial Pathogens.Infectious disease reports · 2023Review
- In Vitro Antifungal Activity of Three Synthetic Peptides againstAntibiotics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
Fungal infections have increased in recent decades with considerable morbidity and mortality, mainly in immunosuppressed or admitted-to-the-ICU patients. The fungal resistance to conventional antifungal treatments has become a public health problem, especially with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.